ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,068.80
0.30%
US Tech 100
21,444.73
0.06%
다우존스 지수
43,661.44
0.49%
Bitcoin
104,380.04
-1.67%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) 뉴스

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:KPTI
일자시간출처헤드라인심볼기업
2024/12/1706:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/12/0922:00PR Newswire (US)Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/12/0606:35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/12/0606:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/12/0321:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/12/0321:00PR Newswire (US)Karyopharm Therapeutics Provides Endometrial Cancer Program UpdateNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/12/0221:00PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/2521:00PR Newswire (US)Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/2306:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/2106:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/2106:05PR Newswire (US)Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/1506:22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0906:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0706:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0522:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0521:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0521:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0521:30PR Newswire (US)Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/11/0205:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/10/3121:00PR Newswire (US)Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/10/3120:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/10/3120:30PR Newswire (US)Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/10/3105:30PR Newswire (US)Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/10/0205:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
2024/09/1805:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/09/0605:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/09/0605:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/09/0605:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/09/0605:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
2024/09/0405:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
 검색 관련기사 보기:NASDAQ:KPTI

최근 히스토리

CCOM
US30
US 30
AMEX
XLF
Financial Select Sector
USI
USTECH100
US Tech 100
COIN
SOLUSD
Solana
NYSE
BAC
Bank of America
NASDAQ
NVDA
NVIDIA
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
COIN
DOGEUSD
Dogecoin
NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
NYSE
CVX
Chevron
COIN
XRPUSD
Ripple
FX
USDGBP
US Dollar vs Sterling
NYSE
AXP
American Express
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유